APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Stromal Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Gastrointestinal Stromal Tumor Drug Industry Research Report 2026

28 December 2025146 pages

Choose your research edition.

Industry ResearchGastrointestinal Stromal Tumor Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Stromal Tumor Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Stromal Tumor Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Gastrointestinal Stromal Tumor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Gastrointestinal Stromal Tumor Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Stromal Tumor Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Gastrointestinal Stromal Tumor Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Gastrointestinal Stromal Tumor Drug Market by Company

China Biopharmaceuticals

Zai Lab

CSPC Pharmaceuticals

Novartis

Mylan Pharms Inc.

Kelun Pharmaceuticals

CStone Pharmaceuticals

Hansoh Pharmaceuticals

Vannsh Life Sciences

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceuticals

MSN Laboratories

Glenmark Pharmaceuticals Ltd.

Drug International

Dr. Reddy's Laboratories

Deciphera Pharmaceuticals

Bulat Pharmaceutical

Beacon Pharmaceuticals

Bayer Pharmaceuticals

Apotex Inc.

Actavis Generics

Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib

Regorafenib

Sunitinib

Imatinib

Others

Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital

Clinic

Others

Gastrointestinal Stromal Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Gastrointestinal Stromal Tumor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Gastrointestinal Stromal Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Gastrointestinal Stromal Tumor Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Gastrointestinal Stromal Tumor Drug Revenue of Manufacturers (2021-2026) Table 9. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Gastrointestinal Stromal Tumor Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Type & Application Table 14. Global Gastrointestinal Stromal Tumor Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Gastrointestinal Stromal Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. China Biopharmaceuticals Company Information Table 19. China Biopharmaceuticals Business Overview Table 20. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 22. China Biopharmaceuticals Recent Developments Table 23. Zai Lab Company Information Table 24. Zai Lab Business Overview Table 25. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio Table 27. Zai Lab Recent Developments Table 28. CSPC Pharmaceuticals Company Information Table 29. CSPC Pharmaceuticals Business Overview Table 30. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 32. CSPC Pharmaceuticals Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio Table 37. Novartis Recent Developments Table 38. Mylan Pharms Inc. Company Information Table 39. Mylan Pharms Inc. Business Overview Table 40. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 42. Mylan Pharms Inc. Recent Developments Table 43. Kelun Pharmaceuticals Company Information Table 44. Kelun Pharmaceuticals Business Overview Table 45. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 47. Kelun Pharmaceuticals Recent Developments Table 48. CStone Pharmaceuticals Company Information Table 49. CStone Pharmaceuticals Business Overview Table 50. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 52. CStone Pharmaceuticals Recent Developments Table 53. Hansoh Pharmaceuticals Company Information Table 54. Hansoh Pharmaceuticals Business Overview Table 55. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 57. Hansoh Pharmaceuticals Recent Developments Table 58. Vannsh Life Sciences Company Information Table 59. Vannsh Life Sciences Business Overview Table 60. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio Table 62. Vannsh Life Sciences Recent Developments Table 63. Teva Pharmaceutical Industries Ltd. Company Information Table 64. Teva Pharmaceutical Industries Ltd. Business Overview Table 65. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 67. Teva Pharmaceutical Industries Ltd. Recent Developments Table 68. Sun Pharmaceuticals Company Information Table 69. Sun Pharmaceuticals Business Overview Table 70. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 72. Sun Pharmaceuticals Recent Developments Table 73. MSN Laboratories Company Information Table 74. MSN Laboratories Business Overview Table 75. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 77. MSN Laboratories Recent Developments Table 78. Glenmark Pharmaceuticals Ltd. Company Information Table 79. Glenmark Pharmaceuticals Ltd. Business Overview Table 80. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 82. Glenmark Pharmaceuticals Ltd. Recent Developments Table 83. Drug International Company Information Table 84. Drug International Business Overview Table 85. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio Table 87. Drug International Recent Developments Table 88. Dr. Reddy's Laboratories Company Information Table 89. Dr. Reddy's Laboratories Business Overview Table 90. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 92. Dr. Reddy's Laboratories Recent Developments Table 93. Deciphera Pharmaceuticals Company Information Table 94. Deciphera Pharmaceuticals Business Overview Table 95. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 97. Deciphera Pharmaceuticals Recent Developments Table 98. Bulat Pharmaceutical Company Information Table 99. Bulat Pharmaceutical Business Overview Table 100. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio Table 102. Bulat Pharmaceutical Recent Developments Table 103. Beacon Pharmaceuticals Company Information Table 104. Beacon Pharmaceuticals Business Overview Table 105. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 107. Beacon Pharmaceuticals Recent Developments Table 108. Bayer Pharmaceuticals Company Information Table 109. Bayer Pharmaceuticals Business Overview Table 110. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 112. Bayer Pharmaceuticals Recent Developments Table 113. Apotex Inc. Company Information Table 114. Apotex Inc. Business Overview Table 115. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 117. Apotex Inc. Recent Developments Table 118. Actavis Generics Company Information Table 119. Actavis Generics Business Overview Table 120. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio Table 122. Actavis Generics Recent Developments Table 123. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 124. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026) & (K Units) Table 125. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021-2026) Table 126. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2027-2032) & (K Units) Table 127. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2027-2032) Table 128. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2021-2026) & (US$ Million) Table 129. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021-2026) Table 130. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2027-2032) & (US$ Million) Table 131. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2027-2032) Table 132. North America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 134. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 135. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 139. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 140. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 144. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 145. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. South America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. South America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 149. South America Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 150. South America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 151. South America Gastrointestinal Stromal Tumor Drug Revenue by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 154. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2027-2032) & (US$ Million) Table 157. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 158. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027-2032) & (K Units) Table 159. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2026) Table 160. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2027-2032) Table 161. Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 162. Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 163. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2026) Table 164. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2027-2032) Table 165. Global Gastrointestinal Stromal Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 166. Global Gastrointestinal Stromal Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 167. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 168. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027-2032) & (K Units) Table 169. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2026) Table 170. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2027-2032) Table 171. Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2026) Table 174. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2027-2032) Table 175. Global Gastrointestinal Stromal Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 176. Global Gastrointestinal Stromal Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Gastrointestinal Stromal Tumor Drug Distributors List Table 180. Gastrointestinal Stromal Tumor Drug Customers List Table 181. Gastrointestinal Stromal Tumor Drug Industry Trends Table 182. Gastrointestinal Stromal Tumor Drug Industry Drivers Table 183. Gastrointestinal Stromal Tumor Drug Industry Restraints Table 184. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Gastrointestinal Stromal Tumor Drug Product Image Figure 5. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Gastrointestinal Stromal Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Gastrointestinal Stromal Tumor Drug Sales (2021-2032) & (K Units) Figure 8. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Ripretinib Product Image Figure 10. Regorafenib Product Image Figure 11. Sunitinib Product Image Figure 12. Imatinib Product Image Figure 13. Others Product Image Figure 14. Hospital Product Image Figure 15. Clinic Product Image Figure 16. Others Product Image Figure 17. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Gastrointestinal Stromal Tumor Drug Sales by Region in 2025 Figure 23. Global Gastrointestinal Stromal Tumor Drug Revenue by Region in 2025 Figure 24. North America Gastrointestinal Stromal Tumor Drug Market Size by Country in 2025 Figure 25. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 26. North America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Gastrointestinal Stromal Tumor Drug Market Size by Country in 2025 Figure 31. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country in 2025 Figure 44. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021-2032) Figure 46. China Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Gastrointestinal Stromal Tumor Drug Market Size by Country in 2025 Figure 55. South America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 56. South America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country in 2025 Figure 62. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021-2032) Figure 64. Egypt Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2032) Figure 70. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2032) Figure 71. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2021-2032) Figure 72. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2032) Figure 73. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2032) Figure 74. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2021-2032) Figure 75. Gastrointestinal Stromal Tumor Drug Value Chain Figure 76. Gastrointestinal Stromal Tumor Drug Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ripretinib
  • Regorafenib
  • Sunitinib
  • Imatinib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • China Biopharmaceuticals
  • Zai Lab
  • CSPC Pharmaceuticals
  • Novartis
  • Mylan Pharms Inc.
  • Kelun Pharmaceuticals
  • CStone Pharmaceuticals
  • Hansoh Pharmaceuticals
  • Vannsh Life Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceuticals
  • MSN Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Drug International
  • Dr. Reddy's Laboratories
  • Deciphera Pharmaceuticals
  • Bulat Pharmaceutical
  • Beacon Pharmaceuticals
  • Bayer Pharmaceuticals
  • Apotex Inc.
  • Actavis Generics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size (2021-2032)
  4. 2.2.2 Global Gastrointestinal Stromal Tumor Drug Sales (2021-2032)
  5. 2.2.3 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2021-2032)
  6. 2.3 Gastrointestinal Stromal Tumor Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ripretinib
  9. 2.3.3 Regorafenib
  10. 2.3.4 Sunitinib
  11. 2.3.5 Imatinib
  12. 2.3.6 Others
  13. 2.4 Gastrointestinal Stromal Tumor Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Clinic
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Gastrointestinal Stromal Tumor Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Gastrointestinal Stromal Tumor Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Gastrointestinal Stromal Tumor Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Gastrointestinal Stromal Tumor Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Gastrointestinal Stromal Tumor Drug, Established Date
  9. 3.9 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 China Biopharmaceuticals
  2. 4.1.1 China Biopharmaceuticals Company Information
  3. 4.1.2 China Biopharmaceuticals Business Overview
  4. 4.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  6. 4.1.5 China Biopharmaceuticals Recent Developments
  7. 4.2 Zai Lab
  8. 4.2.1 Zai Lab Company Information
  9. 4.2.2 Zai Lab Business Overview
  10. 4.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
  12. 4.2.5 Zai Lab Recent Developments
  13. 4.3 CSPC Pharmaceuticals
  14. 4.3.1 CSPC Pharmaceuticals Company Information
  15. 4.3.2 CSPC Pharmaceuticals Business Overview
  16. 4.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  18. 4.3.5 CSPC Pharmaceuticals Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Mylan Pharms Inc.
  26. 4.5.1 Mylan Pharms Inc. Company Information
  27. 4.5.2 Mylan Pharms Inc. Business Overview
  28. 4.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  30. 4.5.5 Mylan Pharms Inc. Recent Developments
  31. 4.6 Kelun Pharmaceuticals
  32. 4.6.1 Kelun Pharmaceuticals Company Information
  33. 4.6.2 Kelun Pharmaceuticals Business Overview
  34. 4.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  36. 4.6.5 Kelun Pharmaceuticals Recent Developments
  37. 4.7 CStone Pharmaceuticals
  38. 4.7.1 CStone Pharmaceuticals Company Information
  39. 4.7.2 CStone Pharmaceuticals Business Overview
  40. 4.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  42. 4.7.5 CStone Pharmaceuticals Recent Developments
  43. 4.8 Hansoh Pharmaceuticals
  44. 4.8.1 Hansoh Pharmaceuticals Company Information
  45. 4.8.2 Hansoh Pharmaceuticals Business Overview
  46. 4.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  48. 4.8.5 Hansoh Pharmaceuticals Recent Developments
  49. 4.9 Vannsh Life Sciences
  50. 4.9.1 Vannsh Life Sciences Company Information
  51. 4.9.2 Vannsh Life Sciences Business Overview
  52. 4.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
  54. 4.9.5 Vannsh Life Sciences Recent Developments
  55. 4.10 Teva Pharmaceutical Industries Ltd.
  56. 4.10.1 Teva Pharmaceutical Industries Ltd. Company Information
  57. 4.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  58. 4.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  60. 4.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  61. 4.11 Sun Pharmaceuticals
  62. 4.11.1 Sun Pharmaceuticals Company Information
  63. 4.11.2 Sun Pharmaceuticals Business Overview
  64. 4.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  66. 4.11.5 Sun Pharmaceuticals Recent Developments
  67. 4.12 MSN Laboratories
  68. 4.12.1 MSN Laboratories Company Information
  69. 4.12.2 MSN Laboratories Business Overview
  70. 4.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  72. 4.12.5 MSN Laboratories Recent Developments
  73. 4.13 Glenmark Pharmaceuticals Ltd.
  74. 4.13.1 Glenmark Pharmaceuticals Ltd. Company Information
  75. 4.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
  76. 4.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  78. 4.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  79. 4.14 Drug International
  80. 4.14.1 Drug International Company Information
  81. 4.14.2 Drug International Business Overview
  82. 4.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
  84. 4.14.5 Drug International Recent Developments
  85. 4.15 Dr. Reddy's Laboratories
  86. 4.15.1 Dr. Reddy's Laboratories Company Information
  87. 4.15.2 Dr. Reddy's Laboratories Business Overview
  88. 4.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  90. 4.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 4.16 Deciphera Pharmaceuticals
  92. 4.16.1 Deciphera Pharmaceuticals Company Information
  93. 4.16.2 Deciphera Pharmaceuticals Business Overview
  94. 4.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  96. 4.16.5 Deciphera Pharmaceuticals Recent Developments
  97. 4.17 Bulat Pharmaceutical
  98. 4.17.1 Bulat Pharmaceutical Company Information
  99. 4.17.2 Bulat Pharmaceutical Business Overview
  100. 4.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
  102. 4.17.5 Bulat Pharmaceutical Recent Developments
  103. 4.18 Beacon Pharmaceuticals
  104. 4.18.1 Beacon Pharmaceuticals Company Information
  105. 4.18.2 Beacon Pharmaceuticals Business Overview
  106. 4.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  108. 4.18.5 Beacon Pharmaceuticals Recent Developments
  109. 4.19 Bayer Pharmaceuticals
  110. 4.19.1 Bayer Pharmaceuticals Company Information
  111. 4.19.2 Bayer Pharmaceuticals Business Overview
  112. 4.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  114. 4.19.5 Bayer Pharmaceuticals Recent Developments
  115. 4.20 Apotex Inc.
  116. 4.20.1 Apotex Inc. Company Information
  117. 4.20.2 Apotex Inc. Business Overview
  118. 4.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  120. 4.20.5 Apotex Inc. Recent Developments
  121. 4.21 Actavis Generics
  122. 4.21.1 Actavis Generics Company Information
  123. 4.21.2 Actavis Generics Business Overview
  124. 4.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
  126. 4.21.5 Actavis Generics Recent Developments
5 Global Gastrointestinal Stromal Tumor Drug Market Scenario by Region
  1. 5.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2027-2032
  5. 5.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2027-2032
  8. 5.4 North America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
  9. 5.4.1 North America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
  41. 5.7.1 South America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Gastrointestinal Stromal Tumor Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Gastrointestinal Stromal Tumor Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
  2. 8.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Gastrointestinal Stromal Tumor Drug Production Mode & Process
  5. 8.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Gastrointestinal Stromal Tumor Drug Distributors
  8. 8.2.3 Gastrointestinal Stromal Tumor Drug Customers
9 Global Gastrointestinal Stromal Tumor Drug Analyzing Market Dynamics
  1. 9.1 Gastrointestinal Stromal Tumor Drug Industry Trends
  2. 9.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
  3. 9.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
  4. 9.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst